Syphilis

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider based on the individual patient's condition, available evidence, and clinical judgment. Always refer to the most current national and international guidelines.

Overview

• Definition: Syphilis is a chronic, systemic sexually transmitted infection (STI) caused by the spirochete Treponema pallidum subspecies pallidum. It is characterized by distinct clinical stages (primary, secondary, latent, tertiary) that can affect virtually any organ system if untreated.
• Epidemiology:
  • Global Incidence: Estimated to affect millions worldwide annually, with increasing incidence in many regions, including the United States and Europe.
  • Demographics: Predominantly affects sexually active individuals. In recent years, increases have been noted among men who have sex with men (MSM), as well as heterosexual men and women, leading to a rise in congenital syphilis.
  • Risk Groups: Higher prevalence among individuals with multiple sexual partners, those engaging in unprotected sex, people with other STIs (especially HIV), and certain marginalized populations.
• Classification: Syphilis is classified into several stages:
  • Early Syphilis:
    • Primary Syphilis: Characterized by a single (or multiple) chancre at the site of inoculation.
    • Secondary Syphilis: Systemic dissemination with mucocutaneous lesions, lymphadenopathy, and constitutional symptoms.
    • Early Latent Syphilis: Asymptomatic infection acquired within the preceding 12 months.
  • Late Syphilis:
    • Late Latent Syphilis: Asymptomatic infection acquired more than 12 months previously or of unknown duration.
    • Tertiary (Late) Syphilis: Affects various organs, including cardiovascular (e.g., aortitis), neurological (neurosyphilis), and dermatological/gastrointestinal (gummatous syphilis).
  • Neurosyphilis: Can occur at any stage of syphilis, involving the central nervous system.
  • Ocular Syphilis: Involvement of the eye, also can occur at any stage.
  • Otosyphilis: Involvement of the ear, can occur at any stage.
  • Congenital Syphilis: Transmitted from mother to fetus during pregnancy.

Pathophysiology

• Mechanism:
  • Treponema pallidum is a highly motile spirochete. Transmission occurs primarily through direct contact with an infectious lesion (chancre, mucous patch, condyloma lata) during sexual activity or vertically from mother to fetus.
  • The spirochete penetrates host mucous membranes or abraded skin, then rapidly disseminates via the lymphatic system and bloodstream throughout the body.
  • Primary Stage: The chancre develops at the site of inoculation, representing the local immune response. It is typically painless, indurated, and ulcerated.
  • Secondary Stage: Occurs weeks to months after the chancre, as T. pallidum disseminates systemically. It causes a generalized skin rash, mucocutaneous lesions, and systemic symptoms due to widespread spirochete replication and immune activation.
  • Latent Stage: The immune system temporarily suppresses the spirochete, leading to an asymptomatic period. Spirochetes persist in lymph nodes and other tissues.
  • Tertiary Stage: In about 15-30% of untreated individuals, after years or decades, localized destructive inflammatory lesions (gummas), cardiovascular complications (e.g., syphilitic aortitis), or neurological complications (neurosyphilis) develop.
  • T. pallidum evades the immune system by having a sparse outer membrane, limiting exposure of antigenic proteins. It can persist intracellularly.
• Risk Factors:
  • Unprotected sexual intercourse (vaginal, anal, oral)
  • Multiple sexual partners
  • Men who have sex with men (MSM)
  • History of other sexually transmitted infections (STIs), particularly HIV infection, which can alter the natural history and presentation of syphilis.
  • Illicit drug use (especially methamphetamine and injection drug use)
  • Commercial sex work
  • Incarceration
  • Lack of access to healthcare and screening
• Protective Factors:
  • Abstinence from sexual activity
  • Consistent and correct use of barrier methods (e.g., condoms) during sexual activity
  • Mutual monogamy with an uninfected partner
  • Regular STI screening, especially for at-risk individuals and pregnant women
  • Prompt diagnosis and treatment of infected individuals and their partners

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Primary Syphilis: Painless, firm, round, indurated ulcer (chancre) typically appearing 10-90 days (average 21 days) post-exposure. Often accompanied by regional, non-tender lymphadenopathy.
  • Secondary Syphilis: Diffuse, symmetrical maculopapular rash (often involving palms and soles) 2-10 weeks after chancre appearance/healing. Other manifestations include condyloma lata (moist, wart-like lesions in anogenital region), mucous patches, generalized lymphadenopathy, alopecia (patchy or moth-eaten), constitutional symptoms (fever, malaise, sore throat, headache), hepatitis, glomerulonephritis.
  • Latent Syphilis: Asymptomatic, detected only by serologic tests.
  • Tertiary Syphilis:
    • Gummatous Syphilis: Chronic, destructive granulomatous lesions affecting skin, bone, or internal organs (e.g., liver, stomach).
    • Cardiovascular Syphilis: Syphilitic aortitis (aneurysm, aortic regurgitation), coronary ostial stenosis.
    • Neurosyphilis: Varied presentation depending on type:
      • Asymptomatic neurosyphilis: CSF abnormalities without clinical symptoms.
      • Meningitis: Headache, stiff neck, cranial nerve palsies, altered mental status.
      • Meningovascular syphilis: Stroke-like symptoms, hemiplegia, aphasia, seizures, due to arteritis.
      • Parenchymatous neurosyphilis:
        • General Paresis: Personality changes, delusions, dementia, tremor, Argyll Robertson pupils (accommodates but does not react to light).
        • Tabes Dorsalis: Ataxia, lightning pains, urinary incontinence, Charcot joints, Argyll Robertson pupils, sensory deficits.
• Early Signs: Chancre (primary), rash, lymphadenopathy, condyloma lata (secondary).
• Advanced Signs: Gummas, aortic aneurysm/regurgitation, stroke-like symptoms, dementia, ataxia (tertiary/neurosyphilis).
• Atypical Presentations:
  • Multiple chancres, painful chancres (especially if co-infected with HSV).
  • Exaggerated rash, bullous rash (rare, more common in HIV-infected or congenital syphilis).
  • Malignant syphilis (lues maligna): Ulcerative, nodular, necrotic lesions, severe constitutional symptoms, often in HIV-infected patients.
  • Acute syphilitic posterior placoid chorioretinopathy (a form of ocular syphilis).

Physical Examination

• Inspection:
  • Skin/Mucosa: Inspect for chancres (genital, anal, oral, pharyngeal), maculopapular rash (including palms and soles), condyloma lata, mucous patches, gummas, alopecia.
  • Eyes: Check for pupillary abnormalities (Argyll Robertson pupils), uveitis, retinal lesions, optic neuritis.
  • Oropharynx: Inspect for mucous patches, chancres.
  • Genitalia/Anus: Thorough inspection for chancres, condyloma lata.
• Palpation:
  • Lymph Nodes: Palpate for regional lymphadenopathy (firm, non-tender, rubbery in primary syphilis) and generalized lymphadenopathy (secondary syphilis).
  • Abdomen: Palpate for hepatosplenomegaly (secondary syphilis).
  • Joints: Assess for signs of Charcot joints (neuropathic arthropathy) in tabes dorsalis.
• Special Tests:
  • Neurological Exam: Detailed assessment for cranial nerve palsies, motor weakness, sensory deficits (proprioception, vibration), reflexes, gait instability, mental status changes (in suspected neurosyphilis).
  • Fundoscopic Exam: For ocular syphilis, to detect optic neuritis or retinitis.
  • Cardiac Auscultation: For cardiovascular syphilis, to detect aortic regurgitation murmurs.

Diagnostic Approach

History Taking

• Key Questions:
  • Sexual History: Number of partners, type of sexual contact (vaginal, anal, oral), condom use, history of STIs, contact with known syphilis cases. Ask about partner's symptoms/diagnosis.
  • Symptoms: Detailed history of any skin lesions, rashes, lumps, sores, fever, fatigue, headaches, vision changes, hearing changes, neurological symptoms, joint pain.
  • Timeline: Onset and progression of symptoms relative to potential exposures.
  • Past Medical History: History of HIV infection, other STIs, prior syphilis diagnosis and treatment.
  • Allergies: Especially to penicillin.
  • Pregnancy Status: For women of childbearing age.
• Red Flags:
  • New onset rash (especially involving palms/soles).
  • Genital/oral/anal ulcer.
  • Unexplained neurological symptoms (e.g., headache, vision changes, hearing loss, gait disturbance, cognitive decline).
  • Pregnant woman with risk factors or positive screening test.
  • HIV-infected individual with any of the above, or a higher RPR/VDRL titer.

Laboratory Tests

Syphilis diagnosis relies primarily on serologic tests, often requiring a two-step algorithm. - First-Line: - Non-treponemal tests (screening and monitoring): - Rapid Plasma Reagin (RPR): Detects antibodies to cardiolipin, a lipid released from damaged host cells. Quantitative, reported as a titer (e.g., 1:8). - Venereal Disease Research Laboratory (VDRL): Similar to RPR, often used for CSF analysis. - Reasoning: These tests become reactive 4-6 weeks after infection or 1-2 weeks after a chancre appears. Titers correlate with disease activity and are used to monitor treatment response. They can be falsely positive in other conditions (e.g., autoimmune diseases, acute infections, pregnancy, IV drug use). - Treponemal tests (confirmatory): - Fluorescent Treponemal Antibody Absorption (FTA-ABS) - T. pallidum Particle Agglutination (TP-PA) - Enzyme Immunoassay (EIA) or Chemiluminescence Immunoassay (CIA) - Reasoning: Detect specific antibodies to T. pallidum antigens. These tests generally remain positive for life, even after successful treatment. They are more specific but cannot differentiate between active and past infection without non-treponemal titers. - Confirmatory: - Traditional Algorithm: Non-treponemal test (RPR or VDRL) first, if reactive, confirm with a treponemal test (FTA-ABS, TP-PA). - Reverse Sequence Algorithm: Treponemal test (EIA or CIA) first, if reactive, confirm with a non-treponemal test (RPR or VDRL). If the non-treponemal test is non-reactive, a third, different treponemal test (e.g., TP-PA) is performed to resolve discrepant results. - Reasoning: The reverse sequence algorithm is common in many laboratories due to automation and higher sensitivity of treponemal tests for screening. However, it can lead to challenges with interpreting positive treponemal, negative non-treponemal results (indicating treated syphilis, early syphilis, or false positive). - Direct Detection (for lesions): - Darkfield Microscopy: Direct visualization of live motile spirochetes from exudates of chancres, condyloma lata, or mucous patches. Rapid but requires specialized equipment and expertise. - Polymerase Chain Reaction (PCR): Can detect T. pallidum DNA from lesion samples, CSF, or other body fluids. Not routinely available in all settings. - Monitoring: - RPR or VDRL titers: Quantitative non-treponemal tests are used to monitor treatment response. A four-fold or greater decrease in titer (e.g., from 1:32 to 1:8) within 6-12 months for early syphilis and 12-24 months for late latent/tertiary syphilis indicates successful treatment. - CSF Analysis (for suspected neurosyphilis): - CSF-VDRL: Highly specific but insensitive. A reactive CSF-VDRL is diagnostic of neurosyphilis. - CSF white blood cell (WBC) count: >5-20 cells/mm³ (depending on HIV status) suggests neurosyphilis. - CSF protein: Elevated protein level (>45-50 mg/dL) supports neurosyphilis. - CSF FTA-ABS: Can be reactive in the absence of neurosyphilis and is not recommended as a sole diagnostic test. - HIV testing: All patients diagnosed with syphilis should be tested for HIV, and vice versa.

Imaging

• Recommended:
  • Brain MRI/CT: In cases of suspected neurosyphilis with focal neurological deficits, to rule out other causes of neurological symptoms (e.g., stroke, tumor) or to detect gummatous lesions, meningeal enhancement, or arteritis.
  • Echocardiography/Aortic Imaging (CT/MRI angiography): For suspected cardiovascular syphilis (e.g., aortic aneurysm, aortic regurgitation), though rare.
• Advanced:
  • PET Scan: Rarely used, but can identify inflammatory gummatous lesions or vascular inflammation in challenging cases.

Management

Acute Management

• Immediate:
  • Diagnosis confirmation: Rapid serologic testing (RPR/VDRL and treponemal test) upon suspicion.
  • Isolation: Not typically required, but counseling on safe sexual practices and avoidance of sexual contact until treatment is complete and lesions have healed is critical.
  • Partner notification: Crucial to prevent further transmission.
• Stabilization:
  • While syphilis itself doesn't typically require "stabilization" in the acute emergency sense, severe manifestations like acute syphilitic meningitis or stroke due to meningovascular neurosyphilis would be managed according to standard neurological emergency protocols, in addition to specific syphilis treatment.
  • Jarisch-Herxheimer Reaction (JHR): An acute febrile reaction (fever, headache, myalgia, rash exacerbation) occurring within 24 hours of syphilis treatment, particularly for early syphilis. It is self-limiting but can be severe. Management is symptomatic (antipyretics, analgesics). Reassure patients it is a sign of treatment working.
• Emergency:
  • Acute Neurosyphilis: Requires prompt hospitalization and intravenous penicillin G to prevent irreversible neurological damage.
  • Ocular Syphilis/Otosyphilis: Managed as neurosyphilis due to potential for permanent vision/hearing loss.

Chronic Management

• Pharmacological: Penicillin G is the drug of choice for all stages of syphilis.
  • Early Syphilis (Primary, Secondary, Early Latent ≤1 year duration):
    • Benzathine Penicillin G: 2.4 million units (MU) administered as a single intramuscular (IM) dose.
    • Reasoning: Single dose achieves treponemicidal levels for an extended period, effective against early, actively multiplying spirochetes.
  • Late Latent Syphilis (>1 year duration or unknown duration):
    • Benzathine Penicillin G: 7.2 MU total, administered as 3 doses of 2.4 MU IM each at 1-week intervals.
    • Reasoning: Longer duration of treatment is needed due to potential for deeper tissue penetration of spirochetes and slower eradication.
  • Tertiary Syphilis (Cardiovascular, Gummatous):
    • Benzathine Penicillin G: 7.2 MU total, administered as 3 doses of 2.4 MU IM each at 1-week intervals.
    • Reasoning: Similar to late latent syphilis, requiring prolonged exposure.
  • Neurosyphilis, Ocular Syphilis, Otosyphilis:
    • Aqueous Crystalline Penicillin G: 18-24 MU per day, administered as 3-4 MU IV every 4 hours or continuous infusion, for 10-14 days.
    • Reasoning: Achieves high, sustained treponemicidal levels in the CSF, crucial for eradicating spirochetes from the central nervous system.
    • Alternative (for patients unable to tolerate IV): Procaine Penicillin G 2.4 MU IM daily PLUS Probenecid 500 mg orally four times a day for 10-14 days. Followed by Benzathine Penicillin G 2.4 MU IM weekly for 3 weeks. (Less preferred than IV aqueous penicillin).
  • Penicillin Allergy:
    • For non-pregnant patients with penicillin allergy and non-neurosyphilis:
      • Doxycycline: 100 mg orally twice daily for 14 days (early syphilis) or 28 days (late latent/tertiary syphilis).
      • Tetracycline: 500 mg orally four times daily for 14 days (early syphilis) or 28 days (late latent/tertiary syphilis).
      • Ceftriaxone: 1 g IM or IV daily for 10-14 days (for early syphilis, some data suggest effectiveness, but not first-line for penicillin allergy).
    • For pregnant patients with penicillin allergy, desensitization to penicillin and treatment with penicillin is recommended.
• Non-pharmacological:
  • Sexual health counseling: Emphasize safe sex practices.
  • Partner notification and treatment: Crucial to prevent reinfection and onward transmission. All sexual partners from the preceding 90 days (for primary/secondary syphilis) or longer (for latent syphilis) should be evaluated and treated presumptively or based on test results.
  • Abstinence: Recommend abstinence from sexual activity until treatment is complete and lesions have resolved.
• Monitoring:
  • Clinical follow-up: Examine for resolution of signs and symptoms.
  • Serologic follow-up: Quantitative non-treponemal tests (RPR or VDRL) are essential.
    • Early Syphilis: Repeat RPR/VDRL at 6 and 12 months post-treatment. A four-fold decrease in titer (e.g., from 1:16 to 1:4) indicates successful treatment.
    • Late Latent/Tertiary Syphilis: Repeat RPR/VDRL at 6, 12, and 24 months post-treatment. Titers may decline more slowly, but a four-fold decrease is still the goal.
    • Neurosyphilis: Repeat CSF analysis (WBC count) at 3 and 6 months post-treatment, then every 6 months until WBC count normalizes. Repeat RPR/VDRL titers as above.
  • HIV testing: Retest for HIV if initial test was negative and risk factors persist.

Treatment Algorithms

• First-Line:
  1. Diagnosis (Serology): Reactive non-treponemal and treponemal tests.
  2. Stage Determination: Based on clinical presentation and duration of infection.
  3. Treatment (Penicillin G):
     • Primary, Secondary, Early Latent: Benzathine Penicillin G 2.4 MU IM single dose.
     • Late Latent, Tertiary (non-neuro): Benzathine Penicillin G 2.4 MU IM weekly for 3 weeks (total 7.2 MU).
     • Neurosyphilis, Ocular, Otosyphilis: Aqueous Crystalline Penicillin G 18-24 MU IV daily for 10-14 days.
  4. Partner Management: Evaluate and treat partners.
  5. Follow-up Serology: Monitor RPR/VDRL titers.
• Second-Line:
  • For penicillin-allergic non-pregnant patients (non-neurosyphilis): Doxycycline or Tetracycline (see Pharmacological section for dosages).
  • For suspected penicillin allergy in pregnant patients or neurosyphilis, penicillin desensitization is typically recommended rather than alternative agents due to efficacy concerns and risk of congenital syphilis.
• Refractory Cases:
  • Treatment failure: Defined as persistently high or increasing non-treponemal titers after adequate treatment, or recurrence of symptoms.
    • Consider re-treatment with a more intensive regimen (e.g., for late latent syphilis if early latent was initially given).
    • CSF examination: Rule out neurosyphilis in all cases of treatment failure, regardless of the stage of initial diagnosis.
    • HIV coinfection: Consider in patients with poor treatment response.
    • Reinfections: Rule out new exposures leading to reinfection.

Complications

• Common:
  • Jarisch-Herxheimer Reaction: Acute febrile reaction post-treatment (see Management).
  • Neurosyphilis: Can occur at any stage, leading to varied neurological deficits.
  • Ocular Syphilis: Uveitis, optic neuritis, retinitis, vision loss.
  • Otosyphilis: Hearing loss, tinnitus, vertigo.
• Serious:
  • Cardiovascular Syphilis: Aortic aneurysm, aortic regurgitation, coronary ostial stenosis (can be fatal).
  • Tabes Dorsalis: Progressive demyelination of posterior columns and dorsal roots, leading to severe ataxia, lightning pains, bladder dysfunction.
  • General Paresis: Progressive dementia, personality changes, psychosis.
  • Congenital Syphilis: Severe, multi-systemic disease in infants, including stillbirth, hydrops fetalis, hepatosplenomegaly, rash, bone abnormalities, neurosyphilis, deafness, blindness, skeletal deformities, and dental abnormalities (Hutchinson teeth, mulberry molars).
• Long-term:
  • Irreversible neurological damage (dementia, blindness, deafness).
  • Aortic complications requiring surgery.
  • Gummas causing tissue destruction and scarring.
  • Persistent RPR/VDRL reactivity (serofast state) even after successful treatment.

Prognosis

• Factors:
  • Stage at diagnosis: Earlier stages have an excellent prognosis with appropriate treatment. Late-stage disease (tertiary, neurosyphilis) can lead to irreversible damage.
  • Adequacy of treatment: Proper dosage and duration are critical.
  • HIV co-infection: May lead to more aggressive disease, higher risk of neurosyphilis, and altered treatment response.
  • Patient adherence: To treatment and follow-up.
• Survival:
  • With early diagnosis and appropriate treatment, syphilis is highly curable, and the prognosis is excellent.
  • Untreated syphilis can lead to significant morbidity and mortality, particularly from cardiovascular syphilis and neurosyphilis, often decades after initial infection.
• Quality of Life:
  • Early syphilis generally has minimal impact on quality of life after successful treatment.
  • Late-stage complications (e.g., severe neurological deficits, visual impairment, cardiovascular disease) can severely impair quality of life and functional independence.

Prevention

• Primary: Preventing initial occurrence
  • Safe sexual practices: Consistent and correct use of condoms for all sexual acts.
  • Abstinence or mutual monogamy: With a known uninfected partner.
  • Reduced number of sexual partners: Decreases exposure risk.
  • Avoidance of illicit drug use: Especially injection drug use, which is associated with increased high-risk sexual behaviors.
  • Education and awareness: Public health campaigns on syphilis transmission and prevention.
• Secondary: Early detection and intervention
  • Screening:
    • Routine screening for at-risk individuals: Annually for sexually active MSM; every 3-6 months for MSM with multiple partners.
    • Universal prenatal screening: All pregnant women should be screened for syphilis at their first prenatal visit. Repeat screening in the third trimester (28-32 weeks) and at delivery is recommended for high-risk women or in high-prevalence areas.
    • HIV-infected individuals: Regular screening due to increased risk and potential for altered disease course.
    • Individuals with other STIs: Especially those diagnosed with gonorrhoea or chlamydia.
  • Prompt diagnosis and treatment: For infected individuals and their sexual partners.
  • Partner notification: Effective contact tracing to identify and treat exposed individuals.
• Tertiary: Preventing complications
  • Adequate treatment of all stages: To prevent progression to latent and tertiary syphilis.
  • Regular follow-up and monitoring: As outlined in the "Monitoring" section, to ensure treatment success and detect treatment failure or reinfection early.

Special Populations

• Pediatric:
  • Congenital Syphilis: Transmitted vertically from an infected mother to the fetus.
    • Prevention: Universal prenatal screening and prompt treatment of pregnant women.
    • Presentation: Can range from asymptomatic at birth to severe multi-systemic disease (early congenital syphilis: rash, hepatosplenomegaly, jaundice, anemia, bone abnormalities; late congenital syphilis: interstitial keratitis, Hutchinson teeth, mulberry molars, saddle nose, deafness, neurosyphilis).
    • Diagnosis: Maternal serology, infant serology (non-treponemal titers, sometimes treponemal), physical exam, long bone x-rays, CSF analysis.
    • Treatment: Aqueous Crystalline Penicillin G IV for 10 days for confirmed or highly probable congenital syphilis. Benzathine Penicillin G IM single dose for low-risk asymptomatic infants born to adequately treated mothers if maternal treatment was close to delivery.
• Geriatric:
  • Syphilis is less common but can occur.
  • Presentation of late-stage syphilis (neurosyphilis, cardiovascular syphilis) may be misdiagnosed as age-related conditions (e.g., dementia, stroke, heart disease).
  • Treatment regimens are generally the same as for adults, but comorbidities and drug interactions should be considered.
• Pregnancy:
  • Screening: Universal screening at first prenatal visit, with repeat screening in high-risk women in the third trimester and at delivery.
  • Diagnosis: Standard serologic tests.
  • Treatment: Penicillin G is the only proven treponemicidal drug for preventing congenital syphilis and is safe for pregnant women.
    • Regimens are the same as for non-pregnant adults according to stage.
    • Penicillin-allergic pregnant women must undergo penicillin desensitization and then be treated with penicillin.
  • Monitoring: Close serologic follow-up (RPR/VDRL titers monthly) after treatment to ensure success.
  • Jarisch-Herxheimer Reaction: Can occur and may cause uterine contractions or fetal distress; women should be advised to seek obstetric care if symptoms occur.
• Comorbidities:
  • HIV Infection:
    • Diagnosis: Serologic tests are generally reliable, but some atypical responses (e.g., delayed seroconversion, higher titers, paradoxical non-treponemal test non-reactivity with secondary syphilis, faster progression) can occur.
    • Clinical Course: HIV-infected individuals may have a higher risk of neurosyphilis and ocular syphilis, potentially with more aggressive or atypical presentations.
    • Treatment: Penicillin G remains the preferred treatment. For early syphilis, some guidelines suggest a second dose of Benzathine Penicillin G after 1 week for HIV-infected individuals, though a single dose is generally effective. Neurosyphilis requires IV aqueous penicillin.
    • Monitoring: Close serologic follow-up is essential, as treatment response may be slower or less robust. CSF examination for neurosyphilis should be considered if clinical or serological response is inadequate.

Clinical Pearls

• Diagnostic:
  • "The Great Imitator": Always consider syphilis in the differential diagnosis for unusual rashes, neurological symptoms, or systemic illness, especially in at-risk individuals.
  • Chancre can be atypical: May be painful, multiple, or located in hidden areas (e.g., anus, mouth, cervix), making it easily missed.
  • Reverse sequence screening pitfalls: A positive treponemal test with a negative non-treponemal test can indicate past treated syphilis, very early infection, or a false positive. Requires careful interpretation and potentially a third treponemal test.
  • CSF examination for neurosyphilis: Crucial if any neurological, ocular, or otic symptoms are present, regardless of syphilis stage. Also, consider if treatment failure or HIV co-infection.
• Treatment:
  • Penicillin is king: It is the only drug with established efficacy for all stages and for preventing congenital syphilis.
  • Desensitize pregnant women: Never use alternatives for penicillin-allergic pregnant women due to risk of congenital syphilis.
  • Jarisch-Herxheimer Reaction: Anticipate it, counsel patients, and manage symptomatically. It is not an allergic reaction.
  • Partner treatment: Critically important to prevent reinfection and spread.
• Pitfalls:
  • Misinterpreting serology: Especially with the reverse sequence algorithm or in the context of HIV.
  • Under-treating latent syphilis: Incorrectly giving a single dose for late latent syphilis can lead to treatment failure.
  • Missing neurosyphilis: Failing to perform a lumbar puncture in appropriate clinical settings.
  • Ignoring penicillin allergy in pregnant women: Using alternative antibiotics could lead to congenital syphilis.
  • Lack of follow-up: Inadequate monitoring of RPR/VDRL titers after treatment.

Recent Updates

• Guidelines: The 2021 CDC STD Treatment Guidelines provide the most current comprehensive recommendations for syphilis diagnosis and management in the United States. WHO also publishes global guidelines.
• Evidence:
  • Ongoing research continues to refine diagnostic algorithms, particularly concerning optimal management of discrepant serological results (positive treponemal, negative non-treponemal).
  • Data on the optimal treatment of syphilis in HIV-infected individuals continues to be evaluated, though current guidelines generally recommend standard penicillin regimens.
  • Increasing focus on congenital syphilis prevention strategies, given rising rates in many countries.
• Controversies:
  • Optimal management of penicillin-allergic non-pregnant patients: While doxycycline is recommended, efficacy data are less robust than for penicillin, and treatment failure rates may be higher. Ceftriaxone is an option, but also lacks extensive comparative efficacy data.
  • Role of CSF examination in asymptomatic patients: Debate continues regarding when to perform CSF examination in asymptomatic HIV-infected individuals with high RPR titers, given the increased risk of neurosyphilis.
  • Serofast state: The significance and management of persistent low-level non-treponemal titers (serofast state) after adequate treatment, particularly in those without clear evidence of ongoing infection or treatment failure.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC): Sexually Transmitted Infections Treatment Guidelines (most recent edition, e.g., 2021). Available at: https://www.cdc.gov/std/treatment-guidelines/default.htm
  • World Health Organization (WHO): Guidelines for the management of sexually transmitted infections (most recent edition). Available at: https://www.who.int/publications/i/item/9789240030089
  • European Centre for Disease Prevention and Control (ECDC): Syphilis diagnosis and management guidelines.
• Studies:
  • Various studies published in infectious disease and public health journals (e.g., Clinical Infectious Diseases, Sexually Transmitted Diseases, The Lancet Infectious Diseases) covering epidemiology, diagnostic test performance, and treatment outcomes. Specific landmark studies related to penicillin efficacy or neurosyphilis management could be cited for in-depth review.
• Reviews:
  • Comprehensive reviews from UpToDate, Harrison's Principles of Internal Medicine, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, and other major medical textbooks.